Drug Database
Back to search

Netherlands· NL-71eabd9e5ea8

TAKHZYRO 150 mg oplossing voor injectie in voorgevulde spuit

A lanadelumab product containing lanadelumab, registered in Netherlands by Takeda Pharmaceuticals International AG Ireland Branch. The same ATC class is registered in 15 of our 19 countries.

ATC B06AC05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedTAKHZYRO 150 mg oplossing voor inject…ATCB06AC05REGISTER NO.NL-71eabd9e5ea8PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lanadelumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lanadelumab is registered in 15 of 19 countries.

Countries holding a registration under ATC B06AC05 (lanadelumab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose
Search lanadelumab products by name

Lanadelumab · ATC B06AC05

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lanadelumab costs, country by country.

Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Lanadelumab · price per daily dose (21.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$857.11
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
LANADELUMAB
Manufacturer
Takeda Pharmaceuticals International AG Ireland Branch
Country
Netherlands (NL)
ATC code
B06AC05
ATC class
Lanadelumab
Defined daily dose
21.4 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/18/1340

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lanadelumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lanadelumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Takhzyro
  • Liechtenstein · Takhzyro
  • Norway · Takhzyro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6593f75f-5a55-4151-9fc0-c4e14f798621
GET /v1/drugs/6593f75f-5a55-4151-9fc0-c4e14f798621?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/takhzyro-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Lanadelumab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130772",
  "excipients": [
    "CITROENZUUR 1-WATER (E 330)",
    "DINATRIUMWATERSTOFFOSFAAT 2-WATER (E 339)",
    "HISTIDINE, (L-)",
    "NATRIUMCHLORIDE",
    "POLYSORBAAT 80 (E 433)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "LANADELUMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2018/11/22",
  "procedure_number": "EMEA/H/C/004806",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/18/1340",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about lanadelumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console